Acute myelogenous leukemia: current treatment and future directions.
about
Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complexCCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.Histamine in cancer immunotherapy.The biological therapy of acute and chronic leukemia.
P2860
Acute myelogenous leukemia: current treatment and future directions.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Acute myelogenous leukemia: current treatment and future directions.
@ast
Acute myelogenous leukemia: current treatment and future directions.
@en
type
label
Acute myelogenous leukemia: current treatment and future directions.
@ast
Acute myelogenous leukemia: current treatment and future directions.
@en
prefLabel
Acute myelogenous leukemia: current treatment and future directions.
@ast
Acute myelogenous leukemia: current treatment and future directions.
@en
P1476
Acute myelogenous leukemia: current treatment and future directions
@en
P2093
D M Mastrianni
P304
P356
10.1016/0002-9343(92)90079-Q
P407
P577
1992-03-01T00:00:00Z